Close Menu

NEW YORK – OpGen said after the close of the market on Friday that it received a notice from Nasdaq that as of June 30 the company does not comply with a listing requirement calling for a minimum shareholder equity of $2.5 million.

As a result, the Gaithersburg, Maryland-based developer of antibiotic-resistance testing technology could face delisting action by Nasdaq. OpGen has 45 calendar days to submit a plan to regain compliance. If Nasdaq accepts the plan, it can grant the company an extension of up to 180 calendar days to become compliant with the listing requirement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The General Data Protection Regulation has slowed some data sharing with non-European researchers as they find ways to comply with the law, ScienceInsider reports.

A bioethicist from Abertay University uses a utilitarian approach to justify genetically modifying the human germline, the BBC reports.

The US has upgraded its network of public health labs to provide whole-genome sequencing to track antibiotic-resistant bacteria, Quartz reports.

In Science this week: approach to visualize 3D genome structure in single cells, RNA interference knockdown screens to examine genetic origins of beetle horns and insect wings,  and more.